Background: Among participants in the Secondary Prevention of Small Subcortical Strokes randomized trial, we sought to identify patients with high versus low rates of recurrent ischemic stroke and to assess effects of aggressive blood pressure control and dual antiplatelet therapy according to risk status. Methods:
Introduction
Small subcortical brain infarcts, commonly known as lacunar strokes, comprise about 25% of ischemic strokes. [1] [2] [3] [4] Most result from intrinsic cerebral small artery disease. Independent risk factors for stroke recurrence in patients with lacunar strokes have not been well delineated in the existing small studies. [5] [6] [7] [8] The Secondary Prevention of Small Subcortical Strokes (SPS3) randomized trial included 3020 patients with recent magnetic resonance imaging (MRI)-defined lacunar strokes and compared dual antiplatelet therapy with clopidogrel plus aspirin versus aspirin alone and, separately, 2 target goals of systolic blood pressure treatment. Here, independent risk factors for recurrent ischemic stroke in SPS3 participants are identified, and the effects of the 2 treatment interventions are assessed according to the risk of stroke recurrence. 9 
Methods
The rationale, design, participant characteristics, and main results of the SPS3 trial have been reported elsewhere. [10] [11] [12] [13] In brief, SPS3 was a randomized, multicenter clinical trial conducted in 82 clinical centers in North America, Latin America, and Spain. Patients of 30 years or older with a recent (#180 days) symptomatic lacunar stroke who were without surgically amenable ipsilateral carotid artery disease or major-risk cardioembolic sources were eligible and randomized simultaneously in a 2-by-2 factorial design, either to single or dual antiplatelet therapy (double blind) and to 1 of 2 target levels of systolic blood pressure control (,130 mm Hg versus 130-149 mm Hg, open label). Participants with a clinical lacunar syndrome were required to meet MRI criteria that included a diffusion-weighted imaging lesion 2.0 cm or less in size with confirmatory apparent diffusion coefficient image or a well-delineated focal hyperintensity of 2.0 cm or less in size on fluid-attenuated inversion recovery (FLAIR) or T2 that corresponded to the clinical syndrome. In addition, MRI evidence of a recent or remote cortical infarct, large (.1.5 cm) subcortical infarct, or prior intracerebral hemorrhage excluded participation (the presence of microbleeds was not an exclusion). MRI eligibility was determined by local investigators, with images submitted for central interpretation by a neuroradiologist. Salient additional exclusion criteria included disabling stroke (modified Rankin scale score $ 4). Patients with prior lacunar stroke or transient ischemic attack (TIA) required a clinical episode antecedent to the qualifying event that was consistent with a classic subcortical ischemic stroke syndrome and not based solely on neuroimaging findings. Diabetics were those with a history of diabetes mellitus at the time of the qualifying stroke (91%) plus those with diabetes diagnosed at the time of stroke (fasting serum glucose $ 120 mg/dL) or initiation of antidiabetic medications during the first 3 months of follow-up (9%). Blood pressure at entry was categorized based on the average of screening systolic blood pressure measurements taken at least 1 week apart, adjusted by adding 5 mm Hg for each antihypertensive medication (up to a maximum of 4) at the time of the measurement. Normotensive was defined as less than 120 mm Hg, prehypertensive as 120 to less than 140 mm Hg, stage I hypertension as 140 to less than 160 mm Hg, and stage II hypertension as 160 mm Hg or more.
These analyses focused on the risk of recurrent ischemic stroke, in contrast to the primary outcome of the SPS3 trials, which also included intracranial hemorrhage (12% of primary events). 12, 13 Recurrent ischemic stroke was clinically defined as a focal neurological deficit of sudden onset persisting for greater than 24 hours with hemorrhage excluded by acute neuroimaging. All strokes were reviewed by a central adjudication committee that was unaware of treatment assignment and that additionally classified ischemic strokes by presumed mechanism based on available diagnostic studies. The antiplatelet trial was terminated 4 months before the blood pressure trial. 12, 13 Here, all ischemic strokes during follow-up in the blood pressure trial are considered. 13 For the analyses of predictors of ischemic stroke, the 238 (98%) recurrent ischemic strokes were combined with 5 (2%) strokes thought to be ischemic but lacking neuroimaging. Recurrent lacunar infarcts (n 5 136) comprised 56% of ischemic strokes, and independent predictors of this subgroup are separately assessed. Patient characteristics selected for inclusion in the analysis were the clinical characteristics reported in a previously published description of participant features 12 plus body mass index, stage of hypertension, and estimated glomerular filtration rate.
14 To identify patient characteristics independently predictive of ischemic stroke, the cohort was randomly divided into 2 groups of equal size, that is, derivation and validation cohorts. Clinical features independently associated with ischemic stroke were identified in the derivation cohort using forward stepwise Cox proportional hazards modeling techniques (likelihood ratio test), both without and with stratification by assigned treatment groups to confirm that treatment assignment did not influence identification of predictors. Independent factors were then combined by inspection in the derivation cohort to yield a risk stratification scheme that was then applied to the validation cohort. Cumulative recurrent stroke rates were compared across risk strata by fitting a Kaplan-Meier curve (log rank test). Annualized stroke rates were calculated with person-years as the denominator with 95% confidence intervals (CIs) computed assuming the Poisson distribution. Absolute differences and CIs in stroke rates between groups were also computed assuming the Poisson distribution. All analyses followed an intention-to-treat paradigm. All tests were 2 sided, and statistical significance was accepted at the .05 level, with no adjustment made for multiple comparisons. Analyses were performed with SPSS version 20.
Results
The mean age (standard deviation) of the cohort was 63 years; 63% were men; and hypertension, diabetes, and ischemic heart disease were present in 75%, 37%, and 10%, respectively (Table 1) . Most participants (65%) were from North America; 51% were white, 30% Hispanic, and 16% black. During 11,046 total years of follow-up (mean follow-up 3.7 years, range 0-8.6 years), there were 243 recurrent ischemic strokes (annualized rate of 2.2% per year). Relative risk reductions by the randomized interventions for recurrent ischemic stroke were 19% (95% CI 24, 37) for dual antiplatelet therapy versus aspirin alone and 15% (95% CI 29, 34) for lower (,130 mm Hg) versus higher (130-149 mm Hg) systolic blood pressure target, with no evidence of treatment interaction (P 5 .3).
Factors Associated with Recurrent Stroke
Male sex, black race, diabetes, and prior symptomatic lacunar stroke or TIA were each independently predictive of recurrent ischemic stroke in the derivation cohort (each P # .01), and these risk factors (each P # .05) except male sex (P 5 .2) were confirmed in the validation cohort (Table 2 ). In the entire cohort, prior symptomatic lacunar were independently predictive of ischemic stroke recurrence. There was no significant interaction between either randomized intervention and any of the independent risk factors of recurrent ischemic stroke (each P for interaction $.3). Analysis with stratification by treatment group yielded the same set of predictors in the model, as did analyses according to the duration of observation after trial entry (Supplemental Table 1 ). Exclusion of prior symptomatic lacunar stroke or TIA from the model did not appreciably change the hazard ratio estimates for the remaining 3 predictors (Supplemental Table 2a ). Omitting prior symptomatic lacunar stroke or TIA as a potential risk factor and repeating the analyses in both the derivation and validation cohorts resulted in identification of the same 3 predictors plus aspirin use at the time of qualifying stroke became significantly predictive of recurrence in the derivation cohort (Supplemental Table 2b ).
Risk Stratification for Recurrent Stroke and Effect of Interventions by Risk Status
Considering the 4 independent predictors of recurrent ischemic stroke (Table 2) , patients with prior symptomatic lacunar stroke or TIA had the highest rates of recurrent stroke, 4.3% per year (95% CI 3.4, 5.5) ( Table 3 , Fig 1) . Among those without prior symptomatic lacunar stroke or TIA, patients with 2 or 3 risk factors of diabetes, male sex, and black race (27% of the cohort) had a recurrent stroke rate of 3.1% per year (95% CI 2.6, 3.9).
Patients with none or a single risk factor of diabetes, male sex, or black race (58% of the cohort) had recurrent stroke rate of 1.3% per year (95% CI 1.0, 1.6) ( Table 3) . No subgroup of patients had a significant reduction in recurrent stroke rate by either randomized intervention (Table 4) .
Factors Associated with Recurrent Lacunar Strokes
Of classifiable ischemic stroke recurrences, 70% (136 of 194) were deemed recurrent lacunar strokes by the central adjudication committee (insufficient data were available to classify ischemic stroke subtype for 49 recurrent ischemic strokes).
Significant independent predictors of recurrent lacunar strokes were identical to those for all recurrent ischemic strokes, except that aspirin use at the time of qualifying stroke was statistically significant in the derivation but not the validation or overall (Supplemental Tables 3 and 4) .
Discussion
These analyses of the largest, most carefully followed cohort of patients with MRI-defined lacunar infarction revealed 4 independent predictors of recurrent ischemic stroke: prior symptomatic lacunar stroke or TIA (HR 5 2.2), diabetes (HR 5 2.0), and black race (HR 5 1.7) were the strongest and most consistent independent risk factors, with male sex (HR 5 1.5) weaker and less consistent ( Table 2 ). The randomized interventions (ie, higher versus lower blood pressure management targets and dual antiplatelet therapy versus aspirin) performed similarly in patient subgroups with independent risk factors for recurrent ischemic stroke, with no interaction with risk status (Table 4) . Consequently, the best estimates of the effect of the randomized interventions in subgroups defined by the risk of recurrence are those for all participants.
It is important to note that these analyses were done in a clinical trial cohort with aggressive blood pressure management, high adherence to antiplatelet therapy, and high prevalence of statin therapy that likely contributed to the relatively low ischemic stroke recurrence rate (2.2% per year). Neither baseline blood pressure nor classification at entry as normotension, prehypertension, class I hypertension, and class II hypertension emerged as independently predictive of recurrent ischemic stroke. However, 90% of participants were categorized as hypertensive at study entry, and excellent blood pressure control during follow-up (systolic blood pressure at the last follow-up visit averaged 131 mm Hg among all patients) 12 may have confounded identification of blood pressure at entry as an independent predictor of ischemic stroke recurrence. It was our a priori anecdotal clinical impression that Hispanics with lacunar infarcts had an especially high risk of stroke recurrence. This was not borne out by these analyses, despite a particularly high frequency of diabetes (42%) among Hispanic participants.
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Previous studies of predictors of stroke recurrence in patients with lacunar infarcts have involved smaller numbers of lacunar stroke patients with fewer recurrent strokes (Table 5) . [15] [16] [17] [18] [19] Diabetes has most consistently been associated with recurrent strokes, with hypertension predictive of recurrent stroke in 2 prior studies. 5, 7, 8 As in our analysis, age did not emerge from previous studies as an independent predictor of recurrent stroke. Abbreviations: BP, blood pressure; HR, hazard ratio; NIHSS, National Institutes of Health Stroke Scale; NR, not reported; OR, odds ratio; RR, relative risk.
*Studies published since 1980 in which the diagnosis of lacunar stroke based on brain imaging; imaging predictors were not considered. An additional study based on magnetic resonance imaging evidence of prior silent lacunes reported diabetes and elevated hematocrit to be independently associated with multiple lacunar strokes. 19 yAdjusted for age and sex. zThe OR for male sex was 2.1, for diabetes 2.0, and hypertension .5; none statistically significant. xPrior stroke was not included as a variable.
Independent predictors for recurrent ischemic stroke identified in this cohort of patients with recent lacunar infarcts overlap in part with well-defined predictors of stroke in patients with atrial fibrillation: prior stroke/ TIA and diabetes. 20 However, age and female sex are important and consistent predictors of stroke in atrial fibrillation patients, supporting distinct stroke mechanisms. 20, 21 Prior symptomatic lacunar ischemia, the most powerful predictor to emerge from these analyses, is not a patho-etiologic cause of recurrence per se but more likely a marker of severity of underlying cerebral small artery disease. Prior symptomatic lacunar ischemia was strongly correlated with diabetes (P 5 .004) and a history of hypertension (P , .001) in the SPS3 cohort (Supplemental Table 5 ). However, omitting prior symptomatic lacunar stroke or TIA as a potential risk factor neither strengthened the association between the remaining risk predictors with recurrent ischemic stroke nor resulted in any of the hypertensionrelated variables becoming predictive (Supplemental Tables 2a and 2b ). Hence, we hypothesize that prior symptomatic lacunar stroke or TIA is a surrogate for important, as yet unidentified, factors that were not captured in these analyses that may offer clues to stroke pathogenesis and prevention. The presence of asymptomatic lacunar infarcts detected by neuroimaging may further contribute to stratification of the risk of recurrent stroke 22 and will be explored in subsequent analyses of the SPS3 cohort. Despite vigorous treatments aimed at secondary stroke prevention employed in these participants closely followed in a clinical trial (and hence exceeding that anticipated in most clinical practice settings), these analyses identified 42% of patients with recent lacunar stroke with substantial (.3% per year) rates of ischemic stroke recurrence (Table 3) . For this large fraction of patients with lacunar stroke, exploring additional novel stroke prevention strategies is warranted.
